Ascelia Pharma AB (publ) (ticker: ACE) hereby invites analysts, investors and media to its virtual Capital Markets Day on Wednesday October 21, 2020. Focus of the day will be on Mangoral market opportunity and preparations for commercialization.
Live Q&A webcast
The virtual event consists of presentations from Ascelia Pharma executives followed by a live Q&A webcast. The presentations will be available on Ascelia Pharma’s website http://www.ascelia.com on October 21 at 08:00 a.m. CET.
The livestreamed Q&A webcast with will take place on October 21 from 14:00-15:00 CET. A recording of the Q&A webcast will be published on Ascelia Pharma’s website after the event.
All presentations will be held in English.
Mangoral in focus
The Capital Markets Day will focus on the market opportunity and preparations for commercialization for lead drug candidate Mangoral, currently in ongoing Phase 3 trial.
Registration for the live Q&A webcast
Participation for the live Q&A webcast can register by contacting Ascelia Pharma’s Executive Assistant Delphine Biro at email@example.com. Please confirm your participation no later than October 16, 2020.More information about the Q&A session including dial-in numbers will follow on Ascelia Pharma’s website one week before the event.
The information was submitted for publication, through the agency of the contact persons set out above, at 10.45am CET on September 30, 2020.
About Ascelia Pharma
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Mangoral and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.
Mangoral (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Mangoral, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is currently in Phase 3 development, including the global multi-center SPARKLE study.